Diversified Trust Co Sells 9,417 Shares of BioMarin Pharmaceutical Inc. $BMRN

Diversified Trust Co trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 65.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,880 shares of the biotechnology company’s stock after selling 9,417 shares during the quarter. Diversified Trust Co’s holdings in BioMarin Pharmaceutical were worth $276,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. DNB Asset Management AS raised its position in BioMarin Pharmaceutical by 13.8% in the third quarter. DNB Asset Management AS now owns 1,274,284 shares of the biotechnology company’s stock worth $69,015,000 after acquiring an additional 154,954 shares during the period. Assenagon Asset Management S.A. grew its position in shares of BioMarin Pharmaceutical by 312.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,419,067 shares of the biotechnology company’s stock valued at $84,335,000 after acquiring an additional 1,074,929 shares during the period. Braidwell LP purchased a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $28,596,000. Perpetual Ltd raised its holdings in shares of BioMarin Pharmaceutical by 425.7% in the 4th quarter. Perpetual Ltd now owns 25,621 shares of the biotechnology company’s stock worth $1,523,000 after purchasing an additional 20,747 shares during the period. Finally, Fisher Asset Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 134.2% in the 3rd quarter. Fisher Asset Management LLC now owns 31,726 shares of the biotechnology company’s stock worth $1,718,000 after purchasing an additional 18,181 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on BMRN shares. HC Wainwright reissued a “neutral” rating on shares of BioMarin Pharmaceutical in a research report on Monday. Royal Bank Of Canada reissued a “sector perform” rating and issued a $66.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, May 5th. Morgan Stanley lowered their price target on shares of BioMarin Pharmaceutical from $120.00 to $119.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th. Barclays upped their price target on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Finally, Sanford C. Bernstein reduced their price objective on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $88.67.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 3,281 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total value of $176,681.85. Following the transaction, the executive vice president directly owned 51,818 shares of the company’s stock, valued at $2,790,399.30. The trade was a 5.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is currently owned by insiders.

BioMarin Pharmaceutical Stock Up 2.9%

BMRN opened at $59.00 on Friday. BioMarin Pharmaceutical Inc. has a 12 month low of $49.26 and a 12 month high of $66.28. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. The business’s 50-day moving average price is $54.43 and its 200-day moving average price is $56.51. The company has a market cap of $11.40 billion, a P/E ratio of 43.06, a P/E/G ratio of 0.44 and a beta of 0.25.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.